Status:
UNKNOWN
Ischemic And Bleeding Risk Assessment After TAVR
Lead Sponsor:
Niguarda Hospital
Conditions:
Aortic Valve Stenosis
Transcatheter Aortic Valve Replacement
Eligibility:
All Genders
18+ years
Brief Summary
Transcatheter aortic valve replacement (TAVR) represents an effective treatment to improve symptoms and prognosis in patients with symptomatic severe aortic stenosis (AS) (1-2). Giving an established...
Detailed Description
Nowadays in the post POPULAR-TAVI era, after transcatheter aortic valve replacement (TAVR), an establish uniform approach towards anticoagulation and antithrombotic therapy were established. All pati...
Eligibility Criteria
Inclusion
- Inclusion criteria
- All patients with severe aortic stenosis undergoing TAVR.
- Availability of changes in antithrombotic therapy at 1 month, 90 days, and 1 year after TAVR.
- Exclusion Criteria
- Patients who died during the index procedure
- Patients in triple antithrombotic therapy at discharge
- Patients with a known prognosis less than 1 year at the time of TAVR
Exclusion
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2024
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT06000943
Start Date
August 1 2023
End Date
December 15 2024
Last Update
August 31 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
OLV Hospital
Aalst, Belgium
2
Complejo Asistencial Dr. Sótero del Río
Santiago, Chile
3
Cardiocenter, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady
Prague, Czechia, 10034
4
ASST GOM Niguarda
Milan, Italia, Italy, 20162